Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with proven advanced and progressive RCC of the clear cell type~* Presence of RECIST v.1.1 evaluable lesions, all \< 5 cm~* Performance status: Karnofsky \> 70 %~* Laboratory values: • White blood cells (WBC) \> 3.5 x 109/l • Platelet count \> 150 x 109/l • Hemoglobin \> 6 mmol/l • Total bilirubin \< 2 x upper limit of normal (ULN) • ASAT, ALAT \< 3 x ULN (\< 5 x ULN if liver metastases present) • MDRD ≥ 40 ml/min~* Negative pregnancy test for women of childbearing potential (urine or serum)~* Age over 18 years~* Written informed consent~Exclusion criteria:~* Known or suspected CNS metastases including leptomeningeal metastases. History or clinical evidence of (CNS) metastases (unless they are previously-treated CNS metastases and patients meet all 3 of the following criteria: are asymptomatic, have had no evidence of active CNS metastases for ≥3 months prior to enrollment, and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days)~* Untreated hypercalcemia~* Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors or mTOR inhibitors within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures is allowed , when unirradiated, evaluable lesions elsewhere are present.~* Cardiac disease with New York Heart Association classification of III or IV~* Patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception~* Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgment of the investigator will significantly affect patients' clinical status~* Life expectancy shorter than 4 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lu-177-DOTA-girentuximab (Type: EXPERIMENTAL): Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).